Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.

Fuckar D, Dekanić A, Stifter S, Mustać E, Krstulja M, Dobrila F, Jonjić N.

Int J Surg Pathol. 2006 Jan;14(1):49-55.

PMID:
16501835
3.
4.

COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.

Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C.

Histopathology. 2005 May;46(5):561-8.

PMID:
15842638
6.

Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.

Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.

Pathol Int. 2003 Jul;53(7):422-8.

PMID:
12828606
7.

Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.

Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U, Milde-Langosch K.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1193-201. doi: 10.1007/s00432-011-0984-2. Epub 2011 May 18.

PMID:
21590495
8.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
10.

[Prognostic factors of breast cancer].

Tang P, Wei B, Yang WJ, Liu YS, Bu H.

Zhonghua Bing Li Xue Za Zhi. 2011 Feb;40(2):73-6. Chinese. No abstract available.

PMID:
21426799
11.

Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

12.

Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.

Rao AV, Mohammed WA, Ragoonanan C, Omo-Igbinomwanhia NE.

West Indian Med J. 2002 Mar;51(1):4-9.

PMID:
12089875
13.

Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.

Mustać E, Zamolo G, Petković M, Dordević G, Radić J, Grgurević E, Batinac T.

Coll Antropol. 2008 Sep;32(3):741-6.

PMID:
18982746
14.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

15.

Breast carcinoma in women 35 years and younger: a pathological study.

Fernandopulle SM, Cher-Siangang P, Tan PH.

Pathology. 2006 Jun;38(3):219-22.

PMID:
16753742
17.

Estrogen and progesterone receptor mRNA levels in primary breast cancer: association with patient survival and other clinical and tumor features.

Nagai MA, Marques LA, Yamamoto L, Fujiyama CT, Brentani MM.

Int J Cancer. 1994 Nov 1;59(3):351-6.

PMID:
7927940
18.

Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.

Singh K, Wang Y, Marketkar S, Kalife ET, Steinhoff MM.

Hum Pathol. 2017 Jul;65:123-132. doi: 10.1016/j.humpath.2017.04.016. Epub 2017 Apr 27.

PMID:
28457730
20.

Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.

Aryandono T, Harijadi, Ghozali A.

Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:600-6.

PMID:
10895217

Supplemental Content

Support Center